Bacopa monnieri 用于 注意力与专注困难
C 证据 来自小型研究的证据有限,但存在一些积极信号。Research suggests Bacopa's modulation of dopamine and acetylcholine systems may support attention and focus. Effects require 8-12 weeks of consistent use for measurable improvement.
结论
Research suggests Bacopa's modulation of dopamine and acetylcholine systems may support attention and focus. Effects require 8-12 weeks of consistent use for measurable improvement.
Key Study Findings
研究人群: ADHD patients (systematic review of supplements)
研究人群: Healthy older adults
研究人群: Retracted publication - invasive ductal carcinoma
研究人群: None
研究人群: None
研究人群: None
Key Statistics
8
研究数量
600
受试者
Positive
等级
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 300-600 mg/day standardized to 50% bacosides
- memorysupport:
- 300 mg/day for minimum 8-12 weeks
上限: Not established; well-tolerated up to 600 mg/day in trials
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | 1861 |
| Bacopa monnieri (Brahmi) | -- | Positive | -- |
| None | 72 weeks | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
最佳服用时间: With meals; effects require 8-12 weeks of consistent use
Safety & Side Effects
已报告的副作用
- ⚠ Gastrointestinal discomfort (nausea, cramping, diarrhea)
- ⚠ Dry mouth
- ⚠ Fatigue in some individuals
- ⚠ Mild sedation at higher doses
已知相互作用
- ● Thyroid medications (may increase thyroid hormone levels)
- ● Anticholinergic drugs (opposes cholinergic enhancement)
- ● Sedative medications (additive CNS depression)
- ● Calcium channel blockers (may enhance blood pressure lowering)
可耐受最高摄入量: Not established; well-tolerated up to 600 mg/day in trials
在开始服用任何补充剂之前,请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Bacopa monnieri help with 注意力与专注困难?
How much Bacopa monnieri should I take for 注意力与专注困难?
Are there side effects of Bacopa monnieri?
How strong is the evidence for Bacopa monnieri and 注意力与专注困难?
Related Evidence
其他成分用于 注意力与专注困难
Bacopa monnieri 用于其他健康状况
References
- [1] Shatha Al Shahab et al.. Nutrients. 2025. Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review. doi:10.3390/nu17091482 PubMed
- [2] Xueyan Feng et al.. Front Pharmacol. 2025. The effect of plant active substances on cognitive function in healthy older adults: a systematic review and network meta-analysis of … doi:10.3389/fphar.2025.1672171 PubMed
- [3] Sohini Roy et al.. Med Oncol. 2024. Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma. doi:10.1007/s12032-024-02365-x PubMed
- [4] John E Lewis et al.. J Clin Transl Res. 2021. The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. PubMed
- [5] Brittany R Block et al.. Sr Care Pharm. 2021. Online Promotion of "Brain Health" Supplements. doi:10.4140/TCP.n.2021.489 PubMed
- [6] Andrea Brioschi Guevara et al.. Alzheimers Res Ther. 2021. Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6. doi:10.1186/s13195-021-00844-1 PubMed
- [7] Michelle D Nemetchek et al.. J Ethnopharmacol. 2017. The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain. doi:10.1016/j.jep.2016.07.073 PubMed
- [8] Grace M McPhee et al.. Med Hypotheses. 2016. Cognitive training and Bacopa monnieri: Evidence for a combined intervention to alleviate age associated cognitive decline. doi:10.1016/j.mehy.2016.09.002 PubMed
- [9] Ananya Sadhu et al.. Clin Drug Investig. 2014. Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product. doi:10.1007/s40261-014-0235-9 PubMed
- [10] P M Kidd. Altern Med Rev. 1999. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. PubMed
FDA 免责声明: 这些声明未经美国食品药品监督管理局(FDA)评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析,不构成医疗建议。在开始任何补充剂方案之前,请务必咨询您的医疗保健提供者。